<DOC>
	<DOCNO>NCT00474201</DOCNO>
	<brief_summary>This study determine whether protease inhibitor lopinavir/ ritonavir ( Kaletra ( Trademark ) ) , use treat HIV disease , lower blood level lipid-regulating drug gemfibrozil ( Lopid ( Trademark ) ) HIV-negative healthy volunteer . Many patient HIV infection take protease inhibitor abnormally high lipid ( cholesterol triglyceride ) . Gemfibrozil , commonly use treat high triglyceride , often effective HIV-infected patient take protease inhibitor , possibly interaction two medicine cause lower gemfibrozil 's level blood . Results study give researcher information whether lopinavir/ ritonavir affect blood level gemfibrozil . Healthy , normal volunteer 18 65 year old test negative HIV may eligible study . On study day 1 , subject blood sample drawn catheter insert vein arm determine pre-dosing blood level gemfibrozil . They take gemfibrozil tablet give breakfast 30 minute take drug . Blood sample obtain catheter 0 , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 , 12 , 24 hour dose determine gemfibrozil level interval . At end 12 hour , catheter remove subject discharge clinic . The next morning subject return clinic another blood sample , collect vein arm . Subjects begin take lopinavir/ ritonavir 7 35 day first dose , depend schedule clinic schedule . On fourteenth day dose subject come clinic give single dose gemfibrozil , study day 1 , breakfast 30 minute later . Blood sample collect determine gemfibrozil level like study day 1 2 . An additional sample collect routine lab test .</brief_summary>
	<brief_title>Drug Interaction Study Lopinavir/Ritonavir Gemfibrozil</brief_title>
	<detailed_description>Hyperlipidemia continue common problem individual HIV , particularly receive HIV protease inhibitor ( PIs ) nucleoside reverse transcriptase inhibitor , stavudine . PI-treated patient note increase low-density lipoprotein ( LDL ) , triglyceride ( TG ) , total cholesterol compare PI-treatment naive individual . The prevalence lipid abnormality patient receive PI-containing therapy estimate 27-57 percent ; moreover , cardiovascular complication begin reveal . Triglyceride elevation , particular , independent risk factor development coronary artery disease , may also lead pancreatitis . Despite treatment fibric acid derivative , gemfibrozil , TGs typically remain elevated upper limit normal HIV-infected subject . One possible reason persistently elevate TGs patient reduce efficacy fibric acid therapy , may result unrecognized drug-drug interaction . Fibric acid derivative metabolize liver via uridine 5'-diphosphate-glucuronosyl transferase enzyme ( UGT ) , induce HIV PI ritonavir . Indeed , ritonavir significantly lower plasma concentration drug metabolize enzymatic system 40-50 percent . As UGT activity induce , metabolism UGT substrates ( gemfibrozil ) increase , result decrease plasma concentration . Preliminary data non-HIV-infected subject suggest reduce plasma concentration gemfibrozil likely result reduce efficacy drug . Despite fact many HIV-infected patient hypertriglyceridemia likely receive triglyceride-lowering therapy fibric acid derivative simultaneously receive antiretroviral therapy include ritonavir ( i.e . lopinavir + ritonavir [ LPV/r ] ) , two drug study combination determine whether interact . The objective study characterize impact LPV/r pharmacokinetic ( PK ) profile gemfibrozil , single 600 mg oral dose , administer healthy volunteer . In longitudinal study design , fifteen subject receive single , 600 mg dose gemfibrozil 13 day LPV/r 400/100 mg twice daily . Gemfibrozil pharmacokinetics determine day one 14 compare use student t-test . Results study provide ( refute ) rationale study design assess possibility dose-adjusting gemfibrozil give combination ritonavir order maximize pharmacologic effect gemfibrozil .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Gemfibrozil</mesh_term>
	<criteria>INCLUSION CRITERIA : Age 18 65 year . Healthy medical history physical exam . Test HIV negative . Screening laboratory value within institutional normal range . Negative serum pregnancy test female childbearing potential within 7 day prior initiation LPV/r . Willingness ability female childbearing potential practice abstinence use effective nonhormonal method birth control ( i.e . condom , diaphragm , IUD , spermicide , etc . ) study . Nonsmoker least 6 week prior study participation . Subjects currently smoke must refrain smoking entire study period . EXCLUSION CRITERIA : Concomitant routine therapy prescription , overthecounter , herbal , holistic medication , include oral contraceptive 30 day prior study participation . Subjects take oral contraceptive currently , within 30 day prior study initiation . Intermittent ( PRN ) use acetaminophen , nonsteroidal antiinflammatory medication ( i.e . ibuprofen ) , loperamide allow study . Subjects allowed take multivitamin mineral , equivalent , daily desire . Inability obtain venous access sample collection . Known presence diabetes mellitus , human immunodeficiency virus ( HIV ) infection , active tuberculosis , cardiac disease ( hypertension ; congestive heart failure etc . ) , renal disease ( chronic acute renal failure insufficiency ) , thyroid disease , hepatitis , respiratory disease ( uncontrolled asthma chronic obstructive pulmonary disease ) , myasthenia gravis , glaucoma , uncontrolled peptic ulcer disease . Any condition may interfere interpretation study result may best interest subject opinion investigator . Positive pregnancy test breastfeed female . The presence persistent diarrhea malabsorption would interfere subject 's ability absorb drug . Drug alcohol use may impair safety adherence . History intolerance allergic reaction ( rash ; hive ; swell lip ; difficulty breathe ) fibric acid derivative ( e.g . gemfibrozil , fenofibrate , bezafibrate , etc . ) protease inhibitor ( ritonavir , lopinavir ; indinavir , nelfinavir , saquinavir , atazanavir , fosamprenavir , darunavir , tipranavir ) . Inability unwillingness female childbearing potential use nonhormonal ( barrier ) method contraception throughout study ( e.g . condom ; diaphragm , etc. ) . Nonfasting total cholesterol triglyceride great equal 270 mg/dL . Participation another study entire study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Pharmacokinetic</keyword>
	<keyword>HIV</keyword>
	<keyword>Drug-Drug Interaction</keyword>
	<keyword>Lopinavir/Ritonavir</keyword>
	<keyword>Gemfibrozil</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>